Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in St. Poelten – page 2

95 clinical trials in St. Poelten, Austria across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

St. Poelten at a glance
95
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

95 trials in St. Poelten

Open in trial search

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:WSG Women's Cancer Study Group GmbH

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hepatitis D

Recruiting

A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BJT-778
  • Sponsor:Mirum Pharmaceuticals Inc.

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Alnylam Pharmaceuticals Inc.

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in St. Poelten

What the registry says about research in the country

01 Cardiovascular Diseases

The cardiovascular diseases research activity in St. Pölten focuses on improving outcomes for people with high-risk heart and vascular conditions. Trials are examining whether new approaches can better reduce major cardiovascular events and ease the burden of complex heart disease.

  • Atherosclerotic cardiovascular disease
  • Elevated lipoprotein(a)
  • Hypertrophic cardiomyopathy

These studies aim to test treatment effectiveness and lower the risk of serious complications in patients with difficult-to-manage cardiovascular conditions.

02 Eye Diseases

Research in eye diseases is centered on neovascular age-related macular degeneration, with an emphasis on making care more practical in everyday clinical settings. The work reflects a strong interest in improving how patients are monitored and treated.

  • Neovascular AMD
  • Real-world treatment assessment

In St. Pölten, this area of research is helping evaluate ways to support better eye care while reducing treatment burden for patients and clinics.

03 Immune System Diseases

Immune system diseases are represented by trials in allergic rhinoconjunctivitis and chronic hepatitis D infection. These studies are exploring new options to manage immune-related conditions and improve symptom control.

  • Birch pollen-induced allergic rhinoconjunctivitis
  • Chronic hepatitis D infection

The research is designed to assess whether emerging therapies can offer better relief or disease control for patients living with persistent immune-driven illnesses.

04 Neoplasms

Neoplasm research in St. Pölten spans both solid tumors and advanced cancer care, including studies in melanoma, hepatocellular carcinoma, and metastatic pancreatic ductal adenocarcinoma. The goal is to improve treatment effectiveness and survival in cancers that can be hard to treat.

  • Melanoma
  • Intermediate-stage hepatocellular carcinoma
  • Metastatic pancreatic ductal adenocarcinoma

These trials are testing new cancer treatment strategies and comparing them with established care to find better options for patients.

05 Virus Diseases

Work in virus diseases is addressing chronic hepatitis D, a serious viral infection that can lead to long-term liver damage. The studies are focused on finding more effective ways to control the disease.

  • Chronic hepatitis D infection

This area of research is aimed at evaluating new therapies against current treatment options and improving care for patients with persistent viral illness.

06 Psychiatry and Psychology

Clinical trials in psychiatry and psychology are centered on mild to moderate major depressive disorder. The research is looking at whether new treatment options can better reduce depressive symptoms and support recovery.

  • Mild to moderate major depressive disorder

These studies are intended to clarify treatment benefit and help identify therapies that may offer meaningful relief for people living with depression.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.